Abstract
Drug addiction manifests as a compulsive drive to take a drug despite serious adverse consequences. This aberrant behaviour has traditionally been viewed as bad 'choices' that are made voluntarily by the addict. However, recent studies have shown that repeated drug use leads to long-lasting changes in the brain that undermine voluntary control. This, combined with new knowledge of how environmental, genetic and developmental factors contribute to addiction, should bring about changes in our approach to the prevention and treatment of addiction.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Persistent impacts of smoking on resting-state EEG in male chronic smokers and past-smokers with 20 years of abstinence
Scientific Reports Open Access 08 March 2023
-
From concepts to treatment: a dialog between a preclinical researcher and a clinician in addiction medicine
Translational Psychiatry Open Access 21 September 2022
-
Cognitive effectiveness of high-intensity interval training for individuals with methamphetamine dependence: a study protocol for randomised controlled trial
Trials Open Access 23 September 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Volkow, N. D., Fowler, J. S. & Wang, G. J. The addicted human brain: insights from imaging studies. J. Clin. Invest. 111, 1444–1451 (2003).
Leshner, A. I. Addiction is a brain disease, and it matters. Science 278, 45–47 (1997).
Nestler, E. J. Molecular basis of long-term plasticity underlying addiction. Nature Rev. Neurosci. 2, 119–128 (2001).
Wagner, F. A. & Anthony, J. C. From first drug use to drug dependence: developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 26, 479–488 (2002).
Spear, L. P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 24, 417–463 (2000).
Sowell, E. R. et al. Mapping cortical change across the human life span. Nature Neurosci. 6, 309–315 (2003).
Adriani, W. et al. Evidence for enhanced neurobehavioral vulnerability to nicotine during periadolescence in rats. J. Neurosci. 23, 4712–4716 (2003).
Kandel, D. B. & Chen, K. Extent of smoking and nicotine dependence in the United States: 1991–1993. Nicotine. Tob. Res. 2, 263–274 (2000).
Slawecki, C. J. & Roth, J. Comparison of the onset of hypoactivity and anxiety-like behavior during alcohol withdrawal in adolescent and adult rats. Alcohol Clin. Exp. Res. 28, 598–607 (2004).
Grant, B. F., Stinson, F. S. & Harford, T. C. Age at onset of alcohol use and DSM-IV alcohol abuse and dependence: a 12-year follow-up. J. Subst. Abuse 13, 493–504 (2001).
Koob, G. F. & Bloom, F. E. Cellular and molecular mechanisms of drug dependence. Science 242, 715–723 (1988).
Di Chiara, G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav. Brain Res. 137, 75–114 (2002).
Wise, R. A. Brain reward circuitry: insights from unsensed incentives. Neuron 36, 229–240 (2002).
Madras, B. K., Fahey, M. A., Bergman, J., Canfield, D. R. & Spealman, R. D. Effects of cocaine and related drugs in nonhuman primates. I. [3H]cocaine binding sites in caudate-putamen. J. Pharmacol. Exp. Ther. 251, 131–141 (1989).
Kreek, M. J., LaForge, K. S. & Butelman, E. Pharmacotherapy of addictions. Nature Rev. Drug Discov. 1, 710–726 (2002).
Schultz, W., Tremblay, L. & Hollerman, J. R. Reward processing in primate orbitofrontal cortex and basal ganglia. Cereb. Cortex 10, 272–284 (2000).
Lu, L., Grimm, J. W., Shaham, Y. & Hope, B. T. Molecular neuroadaptations in the accumbens and ventral tegmental area during the first 90 days of forced abstinence from cocaine self-administration in rats. J. Neurochem. 85, 1604–1613 (2003).
Horvitz, J. C. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 96, 651–656 (2000).
McClure, S. M., Daw, N. D. & Montague, P. R. A computational substrate for incentive salience. Trends Neurosci. 26, 423–428 (2003).
Schultz, W. Reward signaling by dopamine neurons. Neuroscientist 7, 293–302 (2001).
Ito, R., Dalley, J. W., Howes, S. R., Robbins, T. W. & Everitt, B. J. Dissociation in conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats. J. Neurosci. 20, 7489–7495 (2000).
Volkow, N. D., Fowler, J. S., Wang, G. J. & Swanson, J. M. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol. Psychiatry 9, 557–569 (2004).
Robinson, T. E., Gorny, G., Mitton, E. & Kolb, B. Cocaine self-administration alters the morphology of dendrites and dendritic spines in the nucleus accumbens and neocortex. Synapse 39, 257–266 (2001).
Volkow, N. D. & Fowler, J. S. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb. Cortex 10, 318–325 (2000).
McFarland, K., Davidge, S. B., Lapish, C. C. & Kalivas, P. W. Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. J. Neurosci. 24, 1551–1560 (2004).
Martin-Soelch, C. et al. Changes in reward-induced brain activation in opiate addicts. Eur. J. Neurosci. 14, 1360–1368 (2001).
Porrino, L. J., Lyons, D., Smith, H. R., Daunais, J. B. & Nader, M. A. Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains. J. Neurosci. 24, 3554–3562 (2004).
Uhl, G. R. & Grow, R. W. The burden of complex genetics in brain disorders. Arch. Gen. Psychiatry 61, 223–229 (2004).
Laakso, A., Mohn, A. R., Gainetdinov, R. R. & Caron, M. G. Experimental genetic approaches to addiction. Neuron 36, 213–228 (2002).
Chen, C. C. et al. Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. Am. J. Hum. Genet. 65, 795–807 (1999).
Rao, Y. et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. 58, 747–755 (2000).
Kathiramalainathan, K. et al. Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. J. Clin. Psychopharmacol. 20, 435–444 (2000).
Dick, D. M. et al. Association of GABRG3 with alcohol dependence. Alcohol Clin. Exp. Res. 28, 4–9 (2004).
Edenberg, H. J. et al. Variations in GABRA2, encoding the α2 subunit of the GABAA receptor, are associated with alcohol dependence and with brain oscillations. Am. J. Hum. Genet. 74, 705–714 (2004).
Koob, G. F. Stress, corticotropin-releasing factor, and drug addiction. Ann. NY Acad. Sci. 897, 27–45 (1999).
Morgan, D. et al. Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nature Neurosci. 5, 169–174 (2002).
Thanos, P. K. et al. Overexpression of dopamine D2 receptors reduces alcohol self-administration. J. Neurochem. 78, 1094–1103 (2001).
Markou, A., Kosten, T. R. & Koob, G. F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18, 135–174 (1998).
Grant, B. F. et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch. Gen. Psychiatry 61, 807–816 (2004).
Fowler, J. S., Logan, J., Wang, G. J. & Volkow, N. D. Monoamine oxidase and cigarette smoking. Neurotoxicology 24, 75–82 (2003).
Brook, D. W., Brook, J. S., Zhang, C., Cohen, P. & Whiteman, M. Drug use and the risk of major depressive disorder, alcohol dependence, and substance use disorders. Arch. Gen. Psychiatry 59, 1039–1044 (2002).
Johnston, L. D., O'Malley, P. M. & Bachman, J. G. Monitoring the future national survey results on drug use, 1975–2002. Volume I: Secondary school students. National Institutes of Health Publication No. 03-5375, (2003).
Johnston, L. D., O'Malley, P. M., Bachman, J. G. & Schulenberg, J. E. Monitoring the future national survey results on drug use, 1975–2003. Volume I: Secondary school students. National Institutes of Health Publication No. 04-5507, 1–545 (2004).
Block, L. G., Morwitz, V. G., Putsis, W. P., Jr & Sen, S. K. Assessing the impact of antidrug advertising on adolescent drug consumption: results from a behavioral economic model. Am. J. Public Health 92, 1346–1351 (2002).
Flynn, B. S. et al. Long-term responses of higher and lower risk youths to smoking prevention interventions. Prev. Med. 26, 389–394 (1997).
Gruber, A. J. & Pope, H. G., Jr Marijuana use among adolescents. Pediatr. Clin. North Am. 49, 389–413 (2002).
McLellan, A. T., Lewis, D. C., O'Brien, C. P. & Kleber, H. D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284, 1689–1695 (2000).
Schaffer, D. V. & Gage, F. H. Neurogenesis and neuroadaptation. Neuromolecular Med. 5, 1–9 (2004).
Kujala, T. et al. Plastic neural changes and reading improvement caused by audiovisual training in reading-impaired children. Proc. Natl Acad. Sci. USA 98, 10509–10514 (2001).
Fraser, C. et al. Driving plasticity in human adult motor cortex is associated with improved motor function after brain injury. Neuron 34, 831–840 (2002).
Kelley, M. S. & Chitwood, D. D. Effects of drug treatment for heroin sniffers: a protective factor against moving to injection? Soc. Sci. Med. 58, 2083–2092 (2004).
Treatment for cocaine use may have HIV benefits. Study shows how to achieve best results. Aids Alert 18, 118–119 (2003).
Butzin, C. A., Martin, S. S. & Inciardi, J. A. Evaluating component effects of a prison-based treatment continuum. J. Subst. Abuse Treat. 22, 63–69 (2002).
Hiller, M. L., Knight, K. & Simpson, D. D. Prison-based substance abuse treatment, residential aftercare and recidivism. Addiction 94, 833–842 (1999).
Fielding, J. E., Tye, G., Ogawa, P. L., Imam, I. J. & Long, A. M. Los Angeles County drug court programs: initial results. J. Subst. Abuse Treat. 23, 217–224 (2002).
Fulco, C. E., Liverman, C. T. & Earley, L. E. (eds) Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector (Institute of Medicine). (National Academy Press, Washington DC, 1995).
Gfroerer, J. C., Wu, L. -T. & Penne, M. A. Initiation of marijuana use: trends, patterns and implications. SMA 02-3711. Analytic Series A–17. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, Maryland (2002).
Goldstein, R. Z. & Volkow, N. D. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry 159, 1642–1652 (2002).
Fowler, J. S. et al. Low monoamine oxidase B in peripheral organs in smokers. Proc. Natl Acad. Sci. USA 100, 11600–11605 (2003).
Anton, R. F. Pharmacologic approaches to the management of alcoholism. J. Clin. Psychiatry 62 (Suppl. 20), 11–17 (2001).
Johnson, B. A. et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361, 1677–1685 (2003).
Salloum, I. M. et al. Efficacy of valproate maintenance in bipolar alcoholics: a double blind placebo controlled study. Arch. Gen. Psychiatry (in the press).
Johnson, B. A. et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 284, 963–971 (2000).
Mason, B. J., Salvato, F. R., Williams, L. D., Ritvo, E. C. & Cutler, R. B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry 56, 719–724 (1999).
Addolorato, G. et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 37, 504–508 (2002).
Webster, E. L. et al. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137, 5747–5750 (1996).
Fernandez, J. R. & Allison, D. B. Rimonabant Sanofi-Synthelabo. Curr. Opin. Investig. Drugs 5, 430–435 (2004).
George, T. P. & O'Malley, S. S. Current pharmacological treatments for nicotine dependence. Trends Pharmacol. Sci. 25, 42–48 (2004).
George, T. P. et al. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol. Psychiatry 53, 136–143 (2003).
Sellers, E. M., Ramamoorthy, Y., Zeman, M. V., Djordjevic, M. V. & Tyndale, R. F. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine Tob. Res. 5, 891–899 (2003).
Kosten, T. R. & Biegel, D. Therapeutic vaccines for substance dependence. Expert Rev. Vaccines 1, 363–371 (2002).
Krupitsky, E. M. et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J. Subst. Abuse Treat. 26, 285–294 (2004).
Kampman, K. M. et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 75, 233–240 (2004).
Brodie, J. D., Figueroa, E. & Dewey, S. L. Treating cocaine addiction: from preclinical to clinical trial experience with γ-vinyl GABA. Synapse 50, 261–265 (2003).
Raby, W. N. & Coomaraswamy, S. Gabapentin reduces cocaine use among addicts from a community clinic sample. J. Clin. Psychiatry 65, 84–86 (2004).
Gonzalez, G. et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction 98, 1625–1632 (2003).
Shoptaw, S. et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J. Clin. Psychiatry 64, 1440–1448 (2003).
Dackis, C. & O'Brien, C. Glutamatergic agents for cocaine dependence. Ann. NY Acad. Sci. 1003, 328–345 (2003).
Carroll, K. M. et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch. Gen. Psychiatry 61, 264–272 (2004).
Acknowledgements
The authors thank T. Condon, M. Egli, J. Fowler, C. Kassed, R. Litten, A. Noronha and J. Swanson for thoughtful comments and editorial assistance.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Related links
FURTHER INFORMATION
Encyclopedia of Life Sciences
National Institute on Drug Abuse
Rights and permissions
About this article
Cite this article
Volkow, N., Li, TK. Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci 5, 963–970 (2004). https://doi.org/10.1038/nrn1539
Issue Date:
DOI: https://doi.org/10.1038/nrn1539
This article is cited by
-
Persistent impacts of smoking on resting-state EEG in male chronic smokers and past-smokers with 20 years of abstinence
Scientific Reports (2023)
-
Addiction and Volitional Abilities: Stakeholders’ Understandings and their Ethical and Practical Implications
Neuroethics (2023)
-
Common hyper-entropy patterns identified in nicotine smoking, marijuana use, and alcohol use based on uni-drug dependence cohorts
Medical & Biological Engineering & Computing (2023)
-
Cognitive–affective factors underlying disinhibitory disorders and legal implications
Nature Reviews Psychology (2022)
-
From concepts to treatment: a dialog between a preclinical researcher and a clinician in addiction medicine
Translational Psychiatry (2022)